World's Best Scientists 2026 revealed!
Robert L. Schlossman

Robert L. Schlossman

D-Index & Metrics

Medicine

D-Index
86
Citations
29749
World Ranking
14040
National Ranking
7122

Robert L. Schlossman publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Robert L. Schlossman sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 273 publications — 12th percentile

12% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Robert L. Schlossman D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Robert L. Schlossman sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 86 D-Index — 31st percentile

31% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Robert L. Schlossman is affiliated with Harvard University in the United States and has contributed extensively to the fields of medicine and biochemistry, genetics, and molecular biology. Their research primarily focuses on hematology, molecular biology, and oncology, with a notable emphasis on multiple myeloma research and treatments.

The scientist's work covers several specialized topics including:

  • Multiple Myeloma Research and Treatments
  • Cancer Treatment and Pharmacology
  • Protein Degradation and Inhibitors
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Acute Myeloid Leukemia Research
  • Ubiquitin and proteasome pathways
  • Histone Deacetylase Inhibitors Research

Among the recent scholarly articles involving Robert L. Schlossman are:

  • Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma (2022), New England Journal of Medicine
  • Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant (2020), Nature Communications
  • Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins (2021), Cell Reports
  • Risk factors for the development of orthostatic hypotension during autologous stem cell transplant in patients with multiple myeloma (2022), Leukemia & lymphoma/Leukemia and lymphoma
  • Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma (2024), Blood Advances

The venues in which these works have been published include:

  • New England Journal of Medicine
  • Nature Communications
  • Cell Reports
  • Leukemia & lymphoma/Leukemia and lymphoma
  • Blood Advances

Robert L. Schlossman has collaborated frequently with several researchers, including:

  • Paul G. Richardson
  • Jacob P. Laubach
  • Kenneth C. Anderson
  • Nikhil C. Munshi
  • Giada Bianchi

Best Publications

  • Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.

    Teru Hideshima;Dharminder Chauhan;Dharminder Chauhan;Yoshihito Shima;Yoshihito Shima;Noopur Raje;Noopur Raje

  • Lenalidomide after stem-cell transplantation for multiple myeloma

    Philip L. McCarthy;Kouros Owzar;Craig C. Hofmeister;David D. Hurd

  • Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.

    Faith E. Davies;Noopur Raje;Noopur Raje;Noopur Raje;Teru Hideshima;Teru Hideshima;Teru Hideshima;Suzanne Lentzsch;Suzanne Lentzsch;Suzanne Lentzsch

  • Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

    Paul G. Richardson;Robert L. Schlossman;Robert L. Schlossman;Edie Weller;Edie Weller;Teru Hideshima;Teru Hideshima

  • Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.

    Paul G. Richardson;Edie Weller;Sagar Lonial;Andrzej J. Jakubowiak

  • Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

    Jesús F. San-Miguel;Vânia T.M. Hungria;Sung Soo Yoon;Meral Beksac

  • The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.

    Nicholas Mitsiades;Constantine S. Mitsiades;Paul G. Richardson;Vassiliki Poulaki

  • Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications.

    D Gupta;S P Treon;Y Shima;T Hideshima

  • Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

    Teru Hideshima;Constantine Mitsiades;Masaharu Akiyama;Toshiaki Hayashi

  • A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

    Paul G. Richardson;Emily Blood;Constantine S. Mitsiades;Sundar Jagannath

  • Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.

    Constantine S Mitsiades;Nicholas Mitsiades;Vassiliki Poulaki;Robert Schlossman

  • The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications.

    Teru Hideshima;Dharminder Chauhan;Robert Schlossman;Paul Richardson

  • IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade.

    A Ogata;D Chauhan;G Teoh;S P Treon

  • TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications

    Constantine S. Mitsiades;Steven P. Treon;Nicholas Mitsiades;Yoshihito Shima

  • Long-Term Follow-Up of Autologous Bone Marrow Transplantation in Patients With Relapsed Follicular Lymphoma

    Arnold S. Freedman;Donna Neuberg;Peter Mauch;Robert J. Soiffer

  • Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant

    Edwin P. Alyea;Robert J. Soiffer;Christine Canning;Donna Neuberg

  • Molecular sequelae of histone deacetylase inhibition in human malignant B cells

    Nicholas Mitsiades;Constantine S. Mitsiades;Paul G. Richardson;Ciaran McMullan

  • Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity

    Douglas W McMillin;Jake Delmore;Jake Delmore;Ellen Weisberg;Ellen Weisberg;Joseph M Negri;Joseph M Negri

  • Single-Agent Bortezomib in Previously Untreated Multiple Myeloma: Efficacy, Characterization of Peripheral Neuropathy, and Molecular Correlations With Response and Neuropathy

    Paul G. Richardson;Wanling Xie;Constantine Mitsiades;Asher A. Chanan-Khan

  • Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study

    Asher A. Chanan-Khan;Jonathan L. Kaufman;Jayesh Mehta;Paul G. Richardson

Frequent Co-Authors

Paul G. Richardson
Paul G. Richardson Harvard University
Nikhil C. Munshi
Nikhil C. Munshi Harvard University
Kenneth C. Anderson
Kenneth C. Anderson Harvard University
Teru Hideshima
Teru Hideshima Harvard University
Irene M. Ghobrial
Irene M. Ghobrial Harvard University
Constantine S. Mitsiades
Constantine S. Mitsiades Harvard University
Noopur Raje
Noopur Raje Harvard University
Dharminder Chauhan
Dharminder Chauhan Harvard University
Sagar Lonial
Sagar Lonial Emory University
Yu-Tzu Tai
Yu-Tzu Tai Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're interested in alternative healthcare careers or looking for flexible online learning options, there are several paths to consider alongside studying Medicine in the USA. For those holding a non-nursing bachelor’s degree, exploring non nursing bachelor's to msn online programs can provide a fast track into advanced nursing roles.

Prospective nurses in search of accessible programs may want to look into easy nursing schools to get into, which often have less competitive admissions processes. In addition, candidates who prefer to skip entrance exams should consider a nursing school without teas test as a straightforward entry route.

For those interested in healthcare administration, online training options for medical billing and coding are growing rapidly. Check out accredited medical billing and coding schools online with financial aid for flexible, career-focused programs. These related pathways offer a variety of opportunities in the healthcare sector beyond traditional medical degrees.

Best Scientists Citing Robert L. Schlossman

Trending Scientists

Recently Published Articles